April 25, 2013
Kenichi Sugihara, Professor, Tokyo Medical and Dental University Graduate School Bayer Yakuhin’s multi-kinase inhibitor Stivarga (regorafenib) may be recommended as third/forth-line therapy in Japan for patients with unresectable, advanced, recurrent colorectal cancer in the Guidelines for the Treatment of Colorectal...read more